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Timothy Ball, MD,yz Kevin Wheelan, MD,yz Peter A. McCullough, MD, MPHyzxkB leeding in patients with chronic kidneydisease (CKD) or “uremic bleeding” is awell-recognized complication. It has been
described as far back as 1907 by Reisman (1), classi-
cally as a complication of Bright disease. The
continued debate over the mechanism of this disease
only highlights the complicated biochemical milieu
that is present in the blood of patients with CKD.SEE PAGE 2471In this issue of the Journal, Bonde et al. (2) use the
Danish national registries to explore which direction
beneﬁt risk is tipped in patients with CKD receiving
chronic anticoagulation. There are at least 92 known
uremic retention solutes (3), all of which likely play
some role in the body’s essential biochemical func-
tions, and many of which may play a role in the coagu-
lation cascade and platelet function. A number of
factors have been identiﬁed in CKD patients that pro-
mote as well as inhibit coagulation. The untreated pa-
tient with CKD is generally more prone to thrombosis;
however, when treated with antiplatelet agents, hepa-
rin, warfarin, and novel anticoagulants, the same pa-
tient is more prone to bleed than is a patient with
normal renal function. Figure 1 is a detailed, but not
comprehensive list of the commonly identiﬁed pro-
cesses involved (4–7). This complex biologic balance*Editorials published in the Journal of the American College of Cardiology
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controlled trials help to explain the equipoise in
recommendations on anticoagulation in patients with
atrial ﬁbrillation (AF) and CKD. In 2011, the Kidney Dis-
ease Outcomes Quality Initiative committee changed
from recommending anticoagulation for hemodialysis
patients with AF to recommending anticoagula-
tion only as secondary prevention and with close
monitoring (8).
The investigators use an individual-level linkage of
data from several Danish national patient registries to
examine the outcomes of all patients discharged with
nonvalvular AF from 1997 to 2011. A total of 154,259
patients were identiﬁed; 4,419 with pre-dialysis CKD,
and 1,142 receiving renal replacement therapy. They
examined 4 endpoints: composite of death or hospi-
talization from stroke or bleeding; composite of fatal
stroke or fatal bleeding; cardiovascular death; and
all-cause mortality. The study found anticoagulation
in patients with CHA2DS2-VASc (Congestive heart
failure; Hypertension; Age $75 years; Diabetes
mellitus; previous Stroke, transient ischemic attack,
or thromboembolism; Vascular disease; Age 65 to 74
years; Sex category) score >2 to be associated with
better outcomes at all levels of renal function. In pre-
dialysis patients, there was a reduction in composite
endpoints of fatal stroke or fatal bleeding, cardio-
vascular death, and all-cause mortality. In renal
replacement therapy patients, however, there was
only a reduction in all-cause mortality, suggesting
possible confounding by indication and not a thera-
peutic effect of stroke prevention.
Whereas this work has signiﬁcant limitations
inherent to cohort studies, it is among the largest and
most complete datasets analyzing this complex man-
agement question. The investigators acknowledge
that even with rigorous review of the population to
ensure the cohorts were matched, it is impossible to
eliminate some confounding factors. Interestingly, the
FIGURE 1 Effects of CKD on the Coagulation Cascade
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The classic coagulation cascade with the dashed red lines demonstrating a negative effect of chronic kidney disease (CKD)-related factors, and
the dashed slate lines demonstrating a positive effect on the indicated reaction or activation. The factors written in red are decreased in CKD,
whereas the factors in slate are increased. ADP ¼ adenosine diphosphate; GPIb ¼ glycoprotein Ib; GSA ¼ guanidinosuccinic acid;
PAI-1 ¼ plasminogen activator inhibitor-1; PGI2 ¼ prostacyclin; TF ¼ tissue factor; TFPI ¼ tissue factor pathway inhibitor; tPA ¼ tissue plas-
minogen activator; TxA2 ¼ thromboxane A2; vWF ¼ Von Willebrand factor.
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2484overall rates of warfarin use were surprisingly low.
Among those with no CKD, the rate of warfarin use was
23.6% despite 79.2% having a CHA2DS2-VASc score of 2
or higher. For those with CKD and end-stage renal
disease, warfarin was prescribed in fewer than 20% of
patients. It is not known how many patients were
taking dabigatran, rivaroxaban, or apixaban, and thus
a treatment effect from these agents cannot be
excluded. Certain assumptions were made due to
incomplete data. Elements of the CHA2DS2-VASc score,
including hypertension, diabetes, and heart failure,
were compiled based on available ﬁlled prescription
data. Because as little as a 1-point difference in the
CHA2DS2-VASc score can change treatment recom-
mendations, these assumptions carry great weight in
the analysis. It is likely that this method un-
derestimates patients’ risk and lowers the CHA2DS2-
VASc score in the database. With this limitation in
mind, doctors must be very cautious in their interpre-
tation of the reported mortality beneﬁt found in pre-
dialysis patients with a CHA2DS2-VASc of >1.
The results of this study suggest that at any
CHA2DS2-VASc score, the risk of stroke or embolism isroughly double that of non-CKD patients. In all
groups there was a large (4-fold or more) increase in
the rate of bleeding in those in CHA2DS2-VASc $2 with
a smaller step up for CKD and end-stage renal disease.
Thus, one would conclude on balance that there is a
greater opportunity for beneﬁt than harm when the
stroke risk is higher in AF in patients with background
renal disease. This study provides powerful data
about the role of anticoagulation in CKD; however,
additional data are needed in CKD patients with AF to
better understand the role of antiplatelet agents,
warfarin, and the novel anticoagulants. In addition,
the optimal approach to AF and stroke prevention
with end-stage renal disease is still yet to be deﬁned.
For now, these data are helpful to physicians in
choosing warfarin in both advanced CKD patients and
those on dialysis when the CHA2DS2-VASc score is
calculated.
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